Zydus Lifesciences, Formycon Report Positive Pivotal Data for Keytruda Biosimilar FYB206

Zydus Lifesciences Limited has announced the successful clinical development of FYB206, a biosimilar candidate for the immuno-oncology therapy Keytruda (pembrolizumab), marking a milestone towards a filing with the US Food and Drug Administration (USFDA).

According to a regulatory filing, the company’s pivotal Dahlia pharmacokinetic (PK) study met its primary objective. The randomised, double-blind, multi-centre clinical trial demonstrated pharmacokinetic equivalence—or bioequivalence—between FYB206 and the oncology blockbuster reference drug Keytruda. Zydus has in-licensed FYB206 exclusively from Germany-based Formycon AG for commercialisation in the US and Canadian markets.

The company stated that the successful completion of the Dahlia study clears the pathway for a near-term Biologics License Application (BLA) filing with the US FDA. Development teams are focused on completing remaining activities and preparing regulatory dossiers. This progress positions Zydus as a potential "first-wave filer" and a new entrant in the North American immuno-oncology biosimilar market.

"The positive clinical data for the FYB206 marks a key milestone in our collaboration with Formycon and reflects our shared commitment to expand access to affordable, life-saving oncology treatments," Zydus Lifesciences Managing Director Sharvil P Patel said. He added that FYB206 represents the "absolute cornerstone" of the company’s strategic entry into the complex North American immuno-oncology market.

Formycon and the USFDA agreed on a streamlined clinical strategy in early 2025. This pathway aims to demonstrate therapeutic comparability of FYB206 with the reference drug Keytruda based on comprehensive analytical data combined with results from the Dahlia PK study. Formycon is working with regulatory authorities to ensure FYB206 becomes available immediately following the expiration of the reference drug’s exclusivity.

Pembrolizumab is a humanised monoclonal antibody functioning as an immune checkpoint inhibitor, prescribed for a variety of tumour types. The reference drug Keytruda remains one of the world’s best-selling medicines, recording global sales of $31.6 billion in 2025. Zydus stated this figure underscores the substantial demand for oncology treatments and the significant market potential for biosimilars globally.